Ardal et al. / Pull incentives for antibiotics – TATFAR analysis of 6 models

Dear All:

​The TATFAR group has a new and very helpful paper out in Clinical Infectious Diseases in which they analyze 6 different kinds of pull incentives:

  1. Higher reimbursement
  2. Diagnosis confirmation (lower cost for a few days of empiric therapy, higher cost if diagnostics confirm ongoing need)
  3. A fully delinked market entry reward (no sales-based income)
  4. A market-priced market entry reward (some sales-based income)
  5. Tradable exclusivity vouchers, and
  6. An options market-based approach.

After reviewing pros/cons of each, the authors conclude: “It is critical that the implementation of any pull incentive is viewed in the overall context of the broader global strategy to combat AMR. The balance of promoting and rewarding innovation while ensuring patient access and aligning stewardship and public health objectives is necessary in the design of any successful pull incentive.  Strengthening surveillance systems to monitor the incentive are also integral. The incentive that appears able to capture those elements reasonably well while concurrently minimizing secondary disruptive effects is the market entry reward market-priced model.   While the delinked option would likely more effectively stimulate innovation directly benefiting unmet public health needs, we are concerned about the sustainability of the funding levels required.”

This conclusion is consistent with everything else I am seeing. The full analysis is worth reading!

See links below for the full paper … unfortunately, I can’t just post same for sharing as it does not appear to be Open Access.

All best wishes,

–jr

John H. Rex, MD | Chief Medical Officer, F2G Ltd. | Chief Strategy Officer, CARB-X | Expert-in-Residence, Wellcome Trust
Follow me on Twitter: @JohnRex_NewAbx


Link: https://academic.oup.com/cid/article-abstract/doi/10.1093/cid/cix526/3862465/Pull-Incentives-for-Antibacterial-Drug-Development?redirectedFrom=fulltext

Abstract: New alternative market models are needed to incentivize companies to invest in developing new antibacterial drugs.

In a previous publication (*), the Transatlantic Task Force on Antimicrobial Resistance (TATFAR) summarized the key areas of consensus for economic incentives for antibacterial drug development. That work determined that there was substantial agreement on the need for a mixture of push and pull incentives and particularly those that served to de-link the revenues from the volumes sold.

Pull incentives reward successful development by increasing or ensuring future revenue. Several pull incentives have been proposed that could substantially reward the development of new antibacterial drugs.

In this second paper authored by representatives of TATFAR, we examine the advantages and disadvantages of different pull incentives for antibacterial drug development. It is TATFAR’s hope that this analysis combined with other related analyses will provide actionable information that will shape policy makers thinking on this important issue.


* The prior publication is Sciarretta K, Rottingen JA, Opalska A, Van Hengel AJ, Larsen J. Economic Incentives for Antibacterial Drug Development: Literature Review and Considerations From the Transatlantic Task Force on Antimicrobial Resistance. Clinical Infectious Diseases. 2016;63(11):1470-4.

Link: https://academic.oup.com/cid/article-lookup/doi/10.1093/cid/ciw593

Share

Share on twitter
Share on facebook
Share on linkedin
Share on email
Share on whatsapp
Share on reddit

Updating WHO’s Bacterial Priority Pathogen List: Call for advisors

Dear All, Deadline: 15 August 2021: The World Health Organization (WHO) is seeking experts to serve as members of the Advisory Group on the Bacterial Priority Pathogen List (AG BPPL). A “Call for experts” document provides information about the advisory group and the expert profiles being sought for the group. The document also provides information on

FDA-NIAID phage workshop / Social distancing in the 1800s

Dear All, This webinar merits a standalone newsletter! If you are thinking (or working on) phage, then please mark your calendar for an FDA (CBER; Center for Biologics Evaluation and Research) workshop entitled: Science and Regulation of Bacteriophage Therapy: August 30, 2021—September 1, 2021 The purpose of the public workshop is to exchange information with the

Consultants for WHO’s SECURE, Wellcome-ICARS-Danish Gov’t AMR event

Dear All, See below my signature: A 6-month consultancy with WHO to support the the SECURE initiative, a program to assist countries in accessing and sustainably managing new and existing antibiotics needed to cope with antimicrobial resistance (AMR). There’s not much online (yet) about SECURE: the best description I can find is in the Terms of Reference

AMR preparedness: Policy insight & funding call for RNA Readiness and Response (R3)

Dear All, A view from Cambodia: “If we lose this antibiotic, there is no oral treatment left for typhoid here.” Good data drives good policy … it’s a lesson that I’ve really grown to appreciate. With this in mind, Wellcome Trust has just released a report entitled “How drug-resistant infections are undermining modern medicine –

Scroll to Top